Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-analysis

Abstract Background and Aims Epidemiological studies have established an association between psoriasis and inflammatory bowel disease [IBD], i.e. ulcerative colitis [UC] and Crohn’s disease [CD], but results are inconsistent. The aim of this study was therefore to quantify the prevalences and association between IBD and psoriasis. Methods PubMed, Web of Science, and EMBASE were searched from database inception through April 2018 for studies reporting data on psoriasis among patients with IBD and vice versa. Meta-analysis was performed to estimate, respectively, the prevalences and association between IBD and psoriasis. Data extraction was according to the PRISMA guideline, and quality assessment was made using the Newcastle-Ottawa Scale. The main outcomes were the proportion of psoriasis patients with IBD and vice versa, as well as the association (odds ratio [OR]) of IBD in psoriasis and psoriasis in IBD, respectively. Results Based on quantitative analysis of 93 studies, the prevalence of psoriasis in CD and in UC was 3.6% (95% confidence interval [CI] 3.1%–4.6%) and 2.8% [95% CI 2.0%–3.8%] respectively. The prevalence of CD and UC was 0.7% [95% CI 0.2%–1.3%] and 0.5% [95% CI 0.3%–0.8%], respectively, among patients with psoriasis. Presence of CD or UC was significantly associated with psoriasis, with OR 2.0 [95% CI 1.4–2.9] and OR 1.5 [95% CI 1.2–2.0], respectively. Presence of psoriasis was significantly associated with CD: OR 2.2 [95% CI 1.6–3.1] and with UC: OR 1.6 [95% CI 1.3–2.0]. Conclusions We found significant bidirectional associations between psoriasis and IBD, warranting increased awareness among clinicians in the diagnostic process, especially in children and adolescents with IBD. Last, this study showed an increased frequency of paradoxical psoriasis in patients treated with biologics.

Download Full-text

The Bidirectional Association between Inflammatory Bowel Disease and Atopic Dermatitis: A Systematic Review and Meta-Analysis

Dermatology ◽

10.1159/000505290 ◽

2020 ◽

Vol 236 (6) ◽

pp. 546-553 ◽

Cited By ~ 3

Author(s):

Xiao Shi ◽

Qi Chen ◽

Fen Wang

Keyword(s):

Systematic Review ◽

Inflammatory Bowel Disease ◽

Atopic Dermatitis ◽

Bowel Disease ◽

Meta Analysis ◽

Cochrane Library ◽

Bidirectional Association ◽

Newcastle Ottawa Scale ◽

Inflammatory Bowel ◽

Underlying Mechanisms

Background: Previous investigations have suggested a significant association between inflammatory bowel disease (IBD) and atopic dermatitis (AD). Yet, outcomes published remain inconsistent. Objective: To explore the association between IBD and AD by a systematic review and meta-analysis. Methods: A comprehensive search of studies published from March 1, 1968, to July 26, 2019, was performed in electronic databases as follows: PubMed, Embase, Cochrane Library, and Web of Science. Methodological quality was assessed based on the Newcastle-Ottawa Scale. Data analysis was conducted using R version 3.6.1 (meta package version 4.9-7). Results: A total of 14 studies were eligible for exploring the association between IBD and AD. Statistically significant differences were found on the risk of AD comorbidity among patients with IBD (risk ratio [RR] 1.83, 95% CI 1.39–2.40), Crohn’s disease (CD; RR 2.06, 95% CI 1.61–2.64), and ulcerative colitis (UC; RR 1.66, 95% CI 1.23–2.24). Compared with non-AD subjects, patients with AD were 48% (p = 0.019), 44% (p = 0.002), and 38% (p = 0.000) more likely to exhibit IBD, CD as well as UC, respectively. Discussion: Our evidence supported a significant bidirectional association between IBD and AD. Future prospective studies are warranted to explore underlying mechanisms linking them.

Download Full-text

Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis

Medicina ◽

10.3390/medicina56060285 ◽

2020 ◽

Vol 56 (6) ◽

pp. 285

Author(s):

Edoardo Carli ◽

Gian Paolo Caviglia ◽

Rinaldo Pellicano ◽

Sharmila Fagoonee ◽

Stefano Rizza ◽

...

Keyword(s):

Prostate Cancer ◽

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Meta Analysis ◽

Limited Data ◽

Relative Risks ◽

Increased Risk ◽

Pubmed Search ◽

Newcastle Ottawa Scale ◽

Inflammatory Bowel

Background and objectives: Inflammatory bowel disease (IBD) is associated with an increased risk of developing colorectal cancer as well as some extra-intestinal tumors, but there are still limited data about the risk of prostate cancer (PC). To analyze if there is an increased risk of PC in patients affected by IBD, we performed a systematic review with meta-analysis. Materials and Methods: A Pubmed search of all studies comparing standardized incidence ratio (SIR) or odds ratio (OR) or relative risks (RR) of PC between IBD and non IBD groups, published until March 2020 was conducted. The study protocol was registered on PROSPERO. Twelve studies, mostly population studies, were included. The quality score of these studies, evaluated by the Newcastle–Ottawa Scale, was 7. The heterogeneity was high among the studies in which ulcerative colitis (UC) was considered separate from Crohn’s disease (CD) and in the studies that considered UC and CD together (“IBD-studies”), while it was low in the studies which considered CD separate from UC. Results: The relative risk of developing PC was 1.71 (95% confidence interval [CI] 1.16–2.51, p = 0.007) in IBD, 1.10 (95%CI 0.98–1.25, p = 0.116) in CD, and 1.22 (95%CI 0.98–1.51, p = 0.07) in UC. Conclusions: Patients with IBD appear to have a slightly increased risk of PC compared to the general population.

Download Full-text

Effectiveness and safety of acupuncture therapy for inflammatory bowel disease: a protocol of systematic review and meta-analysis

BMJ Open ◽

10.1136/bmjopen-2020-045090 ◽

2021 ◽

Vol 11 (8) ◽

pp. e045090

Author(s):

Yuan-Fang Zhou ◽

Ning Sun ◽

Shi-Rui Cheng ◽

Xiao-Dong Deng ◽

Xiang-Yin Ye ◽

...

Keyword(s):

Systematic Review ◽

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Data Extraction ◽

Meta Analysis ◽

Biomedical Literature ◽

Cochrane Library ◽

China National Knowledge Infrastructure ◽

Inflammatory Bowel ◽

Randomised Controlled

IntroductionPrevious reviews have suggested that the effectiveness of acupuncture for inflammatory bowel disease (IBD) has not well been demonstrated due to the limited randomised controlled trials (RCTs). In recent years, the growing research on acupuncture for IBD make it possible to conduct a further systematic review and synthesise more sufficient clinical data to evaluate the effectiveness and safety of acupuncture for IBD.Methods and analysisNine electronic databases without language restriction will be retrieved from inception to March 2021, including the Cochrane Library, MEDLINE, EMBASE, Ovid, the Allied and Complementary Medicine Database, China National Knowledge Infrastructure, Chinese Biomedical Literature Database, the Chongqing Chinese Science and Technology Periodical Database and Wanfang Database. The RCTs on acupuncture for IBD will be included. The data screening, data extraction and the assessment of risk bias will be performed respectively by two reviewers. The quality of evidence will be evaluated by using the Grading of recommendation Assessment, Development and Evaluation application. The meta-analysis will be performed if heterogeneity analysis conducted on the RevMan software (V.5.3) is insignificant. The primary outcome was symptoms alleviation after acupuncture treatment or even in the follow-up.Ethics and disseminationEthical approval will not be needed because data of this review are not involved in patient’s information and privacy. The results will be published and diffused in a peer-reviewed journal or relative conferences.Trial registration numberCRD42020157903.

Download Full-text

Association between Thiopurines Use and Pregnancy Outcomes in Female Patients with Inflammatory Bowel Disease: A Meta-analysis

Current Pharmaceutical Design ◽

10.2174/1381612826666200916144249 ◽

2020 ◽

Vol 26 ◽

Author(s):

Yang Zhang ◽

Dandan Li ◽

Heng Guo ◽

Weina Wang ◽

Xingang Li ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Preterm Birth ◽

Spontaneous Abortion ◽

Bowel Disease ◽

Pregnancy Outcomes ◽

Congenital Malformations ◽

Meta Analysis ◽

Adverse Pregnancy Outcomes ◽

Inflammatory Bowel ◽

Adverse Pregnancy

Background: Conflicting data exist regarding the influence of thiopurines exposure on adverse pregnancy outcomes in female patients with inflammatory bowel disease (IBD). Objective: The aim of this study was to provide an up-to-date and comprehensive assessment of the safety of thiopurines in pregnant IBD women. Methods: All relevant articles reporting pregnancy outcomes in women with IBD received thiopurines during pregnancy were identified from the databases (PubMed, Embase, Cochrane Library, and ClinicalTrials.gov) with the publication data up to April 2020. Data of included studies were extracted to calculate the relative risk (RR) of multiple pregnancy outcomes: congenital malformations, low birth weight (LBW), preterm birth, small for gestational age (SGA), and spontaneous abortion. The meta-analysis was performed using the random-effects model. Results: Eight studies matched with the inclusion criteria and a total of 1201 pregnant IBD women who used thiopurines and 4189 controls comprised of women with IBD received drugs other than thiopurines during pregnancy were included. Statistical analysis results demonstrated that the risk of preterm birth was significantly increased in the thiopurine-exposed group when compared to IBD controls (RR, 1.34; 95% CI, 1.00-1.79; p=0.049; I 2 =41%), while no statistically significant difference was observed in the incidence of other adverse pregnancy outcomes. Conclusion: Thiopurines’ use in women with IBD during pregnancy is not associated with congenital malformations, LBW, SGA, or spontaneous abortion, but appears to have an association with an increased risk of preterm birth.

Download Full-text

Correction to: Clinical effects and gut microbiota changes of using probiotics, prebiotics or synbiotics in inflammatory bowel disease: a systematic review and meta-analysis

European Journal of Nutrition ◽

10.1007/s00394-021-02592-2 ◽

2021 ◽

Author(s):

Xiao-Feng Zhang ◽

Xiao-Xian Guan ◽

Yu-Jun Tang ◽

Jin-Feng Sun ◽

Xiao-Kai Wang ◽

...

Keyword(s):

Systematic Review ◽

Inflammatory Bowel Disease ◽

Gut Microbiota ◽

Bowel Disease ◽

Meta Analysis ◽

Clinical Effects ◽

Inflammatory Bowel

Download Full-text

Fr546 INTERVENTIONS TO INCREASE VACCINATIONS RATES WITH INFLAMMATORY BOWEL DISEASE AND RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS

Gastroenterology ◽

10.1016/s0016-5085(21)01567-5 ◽

2021 ◽

Vol 160 (6) ◽

pp. S-357

Author(s):

Jalpa Patel ◽

Dina Fakhouri ◽

Mohamed Noureldin ◽

Iris Kovar-Gough ◽

Francis A. Farraye ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Systematic Review ◽

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Meta Analysis ◽

Inflammatory Bowel

Download Full-text

Optimal Range of Fecal Calprotectin for Predicting Mucosal Healing in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Visceral Medicine ◽

10.1159/000514196 ◽

2021 ◽

pp. 1-11

Author(s):

Bing-Jie Xiang ◽

Min Jiang ◽

Ming-Jun Sun ◽

Cong Dai

Keyword(s):

Inflammatory Bowel Disease ◽

Diagnostic Accuracy ◽

Likelihood Ratio ◽

Sensitivity And Specificity ◽

Bowel Disease ◽

Meta Analysis ◽

Positive Likelihood Ratio ◽

Fecal Calprotectin ◽

Mucosal Healing ◽

Inflammatory Bowel

Objective: Fecal calprotectin (FC) is a promising marker for assessment of inflammatory bowel disease (IBD) activity. However, the utility of FC for predicting mucosal healing (MH) of IBD patients has yet to be clearly demonstrated. The objective of our study was to perform a meta-analysis evaluating the diagnostic accuracy of FC in predicting MH of IBD patients. Methods: We systematically searched the databases for studies from inception to April 2020 that evaluated MH in IBD. The methodological quality of each study was assessed according to the Quality Assessment of Diagnostic Accuracy Studies checklist. The extracted data were pooled using a summary receiver operating characteristic curve model. Random-effects model was used to summarize the diagnostic odds ratio, sensitivity, specificity, positive likelihood ratio, and negative likelihood ratio. Results: Sixteen studies comprising 1,682 ulcerative colitis (UC) patients and 4 studies comprising 221 Crohn’s disease (CD) patients were included. The best performance of FC for predicting MH in UC was at cut-off range of 60–75 μg/g with area under the curve (AUC) of 0.88 and pooled sensitivity and specificity of 0.87 and 0.79, respectively. The pooled sensitivity and specificity values of cutoff range 180–250 μg/g for predicting MH in CD were 0.67 and 0.76, respectively. The AUC of 0.79 also revealed improved discrimination for identifying MH in CD with FC concentration. Conclusion: Our meta-analysis has found that FC is a simple, reliable noninvasive marker for predicting MH in IBD patients. FC cutoff range 60–75 μg/g appears to have the best overall accuracy in UC patients.

Download Full-text

IDDF2020-ABS-0094 Use of gastric acid suppressants and risk of disease activity exacerbation in adult patients with inflammatory bowel disease: a systematic review and meta-analysis

10.1136/gutjnl-2020-iddf.74 ◽

2020 ◽

Author(s):

Nikko Theodore Raymundo ◽

Enrik John Aguila ◽

Eric Yasay ◽

Marie Antoinette Lontok

Keyword(s):

Systematic Review ◽

Inflammatory Bowel Disease ◽

Disease Activity ◽

Gastric Acid ◽

Bowel Disease ◽

Meta Analysis ◽

Adult Patients ◽

Risk Of Disease ◽

Inflammatory Bowel

Download Full-text

Ethnic Differences in the Smoking-Related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jjab047 ◽

2021 ◽

Author(s):

Daniele Piovani ◽

Claudia Pansieri ◽

Soumya R R Kotha ◽

Amanda C Piazza ◽

Celia-Louise Comberg ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Latin American ◽

Bowel Disease ◽

Meta Analysis ◽

Study Data ◽

Future Research ◽

Related Risk ◽

Increased Risk ◽

Inflammatory Bowel

Abstract Background and aims The association between smoking and inflammatory bowel disease (IBD) relies on old meta-analyses including exclusively non-Jewish White populations. Uncertainty persists regarding the role of smoking in other ethnicities. Methods We systematically searched Medline/PubMed, Embase and Scopus for studies examining tobacco smoking and the risk of developing IBD, i.e., Crohn’s disease (CD) or ulcerative colitis (UC). Two authors independently extracted study data and assessed each study’s risk-of-bias. We examined heterogeneity and small-study effect, and calculated summary estimates using random-effects models. Stratified analyses and meta-regression were employed to study the association between study-level characteristics and effect estimates. The strength of epidemiological evidence was assessed through prespecified criteria. Results We synthesized 57 studies examining the smoking-related risk of developing CD and UC. Non-Jewish White smokers were at increased risk of CD (29 studies; RR: 1.95, 95% CI: 1.69‒2.24; moderate evidence). No association was observed in Asian, Jewish and Latin-American populations (11 studies; RR: 0.97; 95% CI: 0.83–1.13), with no evidence of heterogeneity across these ethnicities. Smokers were at reduced risk of UC (51 studies; RR: 0.55, 95% CI: 0.48–0.64; weak evidence) irrespectively of ethnicity; however, cohort studies, large studies and those recently published showed attenuated associations. Conclusions This meta-analysis did not identify any increased risk of CD in smokers in ethnicities other than non-Jewish Whites, and confirmed the protective effect of smoking on UC occurrence. Future research should characterize the genetic background of CD patients across different ethnicities to improve our understanding on the role of smoking in CD pathogenesis.

Download Full-text